(S)-N-{6-benzo[1,3]dioxol-5-yl-1-[5-(4-fluoro-benzoyl)-pyridin-3-ylmethyl]-2-oxo-1,2-dihydro-pyridin-3-yl}-2-methylamino-propionamide | 1033123-66-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (S)-N-{6-benzo[1,3]dioxol-5-yl-1-[5-(4-fluoro-benzoyl)-pyridin-3-ylmethyl]-2-oxo-1,2-dihydro-pyridin-3-yl}-2-methylamino-propionamide
• 英文别名: (2S)-N-[6-(1,3-benzodioxol-5-yl)-1-[[5-(4-fluorobenzoyl)pyridin-3-yl]methyl]-2-oxopyridin-3-yl]-2-(methylamino)propanamide
• CAS: 1033123-66-8
• 化学式: C₂₉H₂₅FN₄O₅
• 分子量: 528.54
• InChiKey: YHIYYAVRSCNPTF-KRWDZBQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  39
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Organic Compounds
  申请人：Chen Zhuoliang

  公开号：US20100048571A1

  公开（公告）日：2010-02-25

  The present disclosure relates to XIAP inhibitor compound of the formula I:

  本公开涉及公式I的XIAP抑制剂化合物：
• Antibodies that bind human cannabinoid 1 (CB1) receptor
  申请人：BIRD ROCK BIO, INC.

  公开号：US10308712B2

  公开（公告）日：2019-06-04

  The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.

  本发明涉及结合大麻素 1（CB1）受体的新型抗体及其片段。本文公开的抗体及其片段包括结合 CB1 受体的人源化抗体。本发明还包括这些抗体用于治疗对 CB1 受体的拮抗或激动有反应的疾病或紊乱。
• ORGANIC COMPOUNDS
  申请人：NOVARTIS AG

  公开号：EP2086938A1

  公开（公告）日：2009-08-12
• ANTIBODIES THAT BIND HUMAN CANNABINOID 1 (CB1) RECEPTOR
  申请人：BIRD ROCK BIO, INC.

  公开号：EP3122780A2

  公开（公告）日：2017-02-01
• Polypeptides that bind Trail-R1 and Trail-R2
  申请人：Bowdish Katherine S.

  公开号：US20100105620A1

  公开（公告）日：2010-04-29

  Agonists for TRAIL death receptors including polypeptides having a multimerizing, e.g. trimerizing, domain and a polypeptide sequence that binds to at least one of TRAIL death receptors TRAIL-R1 and TRAIL-R2. Agonists are described that do not bind to TRAIL decoy receptors. The multimerizing domain may be derived from human tetranectin. The agonists can induce apoptosis in pathogenic cells expressing a TRAIL death receptor. Pharmaceutical compositions are described for treating diseases associated with cells expressing DR4 and DR5, such as tumor cells. Methods for selecting polypeptides and preparing multimeric complexes.